Omland Lise H, Lindberg Henriette, Carus Andreas, Als Anne Birgitte, Jensen Niels Viggo, Taarnhøj Gry A, Trepiakas Redas, Suetta Charlotte, Omland Lars H, Pappot Helle
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark.
Eur Urol Open Sci. 2020 Dec 26;24:1-8. doi: 10.1016/j.euros.2020.12.002. eCollection 2021 Feb.
Real-world treatment patterns and survival outcomes of locally advanced, unresectable, and metastatic urinary tract cancer (mUTC) patients have not previously been studied in a nationwide, population-based cohort.
To describe treatment patterns and survival outcomes in mUTC patients treated in the real-world clinical setting.
This nationwide, population-based study included all mUTC patients initiating first-line chemotherapy at Danish oncology departments from January 2010 to March 2016. Data were retrospectively obtained from electronic medical records.
Outcome measurements were descriptive. Kaplan-Meier was used for survival analysis.
Of 952 patients included in the study, 46.2% initiated standard gemcitabine/cisplatin (GC) and 21.1% gemcitabine/carboplatin (CaG); the remaining patients initiated other treatment regimens. Median follow-up was 11.6 mo. The overall response rate and disease control rate were 43.0% and 61.7% in all patients, 51.4% and 69.1% in GC-treated patients, and 34.4% and 58.8% in CaG-treated patients, respectively. Median overall survival (OS) was 11.7 (95% confidence interval [CI]: 10.8-12.5) mo in all patients, 14.0 (95% CI: 12.5-15.5) mo in GC-treated patients, and 9.8 (95% CI: 8.7-10.9) mo in CaG-treated patients. Limitations include the retrospective study design.
Real-world mUTC patients are older and less fit than patients enrolled in clinical trials; despite this, tumor responses and survival are comparable. Survival in our patient cohort is also comparable with that reported from other real-world studies in this patient group.
We studied treatment patterns and survival in urinary tract cancer patients receiving chemotherapy in the real-world clinical practice. Survival in our patient cohort was comparable with that reported from clinical trials and other real-world studies in this patient group.
此前尚未在全国性、基于人群的队列中研究局部晚期、不可切除和转移性尿路上皮癌（mUTC）患者的真实世界治疗模式和生存结果。
描述在真实世界临床环境中接受治疗的mUTC患者的治疗模式和生存结果。
设计、设置和参与者：这项全国性、基于人群的研究纳入了2010年1月至2016年3月在丹麦肿瘤科室开始一线化疗的所有mUTC患者。数据通过回顾性方式从电子病历中获取。
结果测量为描述性的。采用Kaplan-Meier法进行生存分析。
在纳入研究的952例患者中，46.2%开始使用标准吉西他滨/顺铂（GC）方案，21.1%开始使用吉西他滨/卡铂（CaG）方案；其余患者开始使用其他治疗方案。中位随访时间为11.6个月。所有患者的总缓解率和疾病控制率分别为43.0%和61.7%，GC治疗患者分别为51.4%和69.1%，CaG治疗患者分别为34.4%和58.8%。所有患者的中位总生存期（OS）为11.7（95%置信区间[CI]：10.8 - 12.5）个月，GC治疗患者为14.0（95%CI：12.5 - 15.5）个月，CaG治疗患者为9.8（95%CI：8.7 - 10.9）个月。局限性包括回顾性研究设计。
真实世界中的mUTC患者比参加临床试验的患者年龄更大且身体状况更差；尽管如此，肿瘤反应和生存情况具有可比性。我们患者队列中的生存情况也与该患者群体其他真实世界研究报告的情况相当。
我们研究了在真实世界临床实践中接受化疗的尿路上皮癌患者的治疗模式和生存情况。我们患者队列中的生存情况与临床试验及该患者群体其他真实世界研究报告的情况相当。
